 PHILADELPHIA, March 28, 2022 GLOBE NEWSWIRE -- Passage Bio, Inc. NASDAQ: PASG, a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system CNS disorders, today announced that management will participate in the following upcoming virtual investor conferences: 